miscsubjectsAI governance
Evidence review

SS-31 (Elamipretide) and Semaglutide: Mitochondrial Targeting and Metabolic Load Reduction Studied in Separate Contexts

· · 3 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ss-31-semaglutide`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ss-31-semaglutide

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-semaglutide/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-semaglutide/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-semaglutide/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-semaglutide/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why SS-31 (Elamipretide) might help you

  1. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

Why Semaglutide might help you

  1. What keeps failing: Weight-related joint and disc overload; metabolic stress on repair capacity.
  2. What Semaglutide is studied to do: Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.
  3. Therefore for you: If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

How these fit together

Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.

  • SS-31 (Elamipretide) → mitochondrial
  • Semaglutide → metabolic load / body weight

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 4
  • Claims tagged human evidence: 3
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 5

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.46 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Mitochondrial protein interaction landscape of SS-31 (source s1)

Details SS-31 cardiolipin binding and effects on mitochondrial complexes.

Evidence type: Published research.

A Trial to Evaluate Safety and Efficacy of Elamipretide in Primary Mitochondrial Myopathy (source s2)

Phase 3 protocol and design confirming primary endpoint assessment.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

SS-31 treatment ameliorates cardiac mitochondrial dysfunction in a mouse model of Barth syndrome (source s3)

Reports open-label functional improvements from TAZPOWER extension.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Semaglutide exposure and its association with adverse lumbar fusion outcomes (source s4)

Observational human data on post-surgical outcomes with semaglutide.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

semaglutide · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedSS-31 (Elamipretide) and Statin-Associated Cognitive Effects: Evidence… · 2 humanSS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidenc… · 2 humanSS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evid… · 2 humanSS-31 (Elamipretide) for Chemotherapy-Induced Neuropathy: Evidence Rev… · 2 human
Evidence · 5 sources · swipe →chain c19d59625d92 · verify chain · provenance
1 / 5
Evidence ledger 5 · tier-ranked · API
mechanistic
Each pound of body weight lost can reduce lumbar compressive force by approximately four pounds.
sources: s5
humanlow confidence
Phase 3 MMPOWER-3 trial of elamipretide in primary mitochondrial myopathy did not meet primary endpoint.
sources: s2
humanlow confidence
Open-label TAZPOWER extension reported improvements in 6-minute walk test and muscle strength in Barth syndrome.
sources: s3
humanlow confidence
Semaglutide use is associated with higher likelihood of additional lumbar fusion surgery within 1 year post-TLIF (OR 11.79).
sources: s4
mechanisticlow confidence
SS-31 binds cardiolipin in the inner mitochondrial membrane to support electron transport chain efficiency.
sources: s1
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:47
SS-31 (Elamipretide) and Semaglutide: Mitochondrial Targeting and Metabolic Load Reduction Studied in Separate Contexts · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Semaglutide
Slug: ss-31-semaglutide
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"dual_compound","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"},{"id":"semaglutide","name":"Semaglutide"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"W
it output
{
  "slug": "ss-31-semaglutide",
  "title": "SS-31 (Elamipretide) and Semaglutide: Mitochondrial Targeting and Metabolic Load Reduction Studied in Separate Contexts",
  "body": "## What's breaking down\n\nDegeneration often traces to layers where repair capacity falls behind ongoing stress. One layer involves mitochondrial dysfunction: cells lose efficient energy production, accumulate oxidative damage, and trigger broader tissue decline. Another layer centers on excess body weight that increases compressive forces on weight-bearing structures like the spine and joints. Each layer can outpace natural repair mechanisms. The compounds below are discussed only in relation to these studied pathways, not as symptom masks.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial dysfunction contributes to your tissue repair shortfall, SS-31 (Elamipretide) is studied because it targets that specific layer.\n\n1. SS-31 binds cardiolipin in the inner mitochondrial membrane.\n2. This interaction supports electron transport chain efficiency and limits reactive oxygen species leakage.\n3. Better mitochondrial output may support cellular energy needs for repair processes rather than masking downstream effects.\n\n## Why Semaglutide might help you\n\nIf excess body weight adds mechanical stress that overwhelms repair in weight-sensitive tissues, Semaglutide is studied because it tar
9c9e5094f5ec007b
Machine verification: /api/articles/ss-31-semaglutide/contributions

Related articles

semaglutide · condition map

Open evidence map →
Ss 31ss-31SS-31 (Elamipretide) for Benzodiazepine Withdrawal: Mitochondrial Repa…ss-31-benzo-withdrawalSS-31 (Elamipretide) and Benzodiazepines: Mitochondrial Pathways in a…ss-31-benzodiazepinesSS-31 (Elamipretide) and Statin-Associated Cognitive Effects: Evidence…ss-31-brain-fogSS-31 (Elamipretide) for Carpal Tunnel Syndrome: Mitochondrial Evidenc…ss-31-carpal-tunnelSS-31 (Elamipretide) for Chemotherapy Side Effects: Mitochondrial Evid…ss-31-chemo
Ask this article · 7 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Each pound of body weight lost can reduce lumbar compressive force by approximately four pounds."?
ask ss-31-semaglutide claim c5 · paste includes §SELF
What does the ledger say about this (human tier): "Phase 3 MMPOWER-3 trial of elamipretide in primary mitochondrial myopathy did not meet primary endpoint."?
ask ss-31-semaglutide claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Open-label TAZPOWER extension reported improvements in 6-minute walk test and muscle strength in Barth syndrome."?
ask ss-31-semaglutide claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "Semaglutide use is associated with higher likelihood of additional lumbar fusion surgery within 1 year post-TLIF (OR 11.79)."?
ask ss-31-semaglutide claim c4 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "SS-31 binds cardiolipin in the inner mitochondrial membrane to support electron transport chain efficiency."?
ask ss-31-semaglutide claim c1 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) and Semaglutide: Mitochondrial Targeting and Metabolic Load Reduction Studied in Separate Contexts — and what would you need me to tell you first?
ask ss-31-semaglutide condition gaps · paste includes §SELF
What good and bad outcomes are documented for SS-31 (Elamipretide) and Semaglutide: Mitochondrial Targeting and Metabolic Load Reduction Studied in Separate Contexts (studies vs anecdotes)?
ask ss-31-semaglutide good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →
Loading more articles…